Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03058588 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Dec 31, 2025 to Dec 31, 2026v11
  2. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2025v10
  3. Re-verified, no change to tracked fieldsv9
  4. Primary and study completion dates: Dec 31, 2023 to Dec 31, 2024v8
  5. Primary and study completion dates: Dec 31, 2022 to Dec 31, 2023v7
Show 5 earlier versionsHide 5 earlier versions
  1. Primary and study completion dates: Dec 9, 2021 to Dec 31, 2022v6
  2. Primary and study completion dates: Feb 9, 2021 to Dec 9, 2021v5
  3. 3 versions Re-verified since May 2, 2017, no change to tracked fieldsv2-v4
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to look for predisposing mutations in patients and relatives affected by AML and MDS with familial history of myeloid or, less frequently, lymphoid malignancies. Taking advantage of a next generation sequencing (NGS) platform, screening for known and unknown mutations potentially associated with the disease will be done. The screening will be performed on affected and unaffected family members, in order to outline new pedigrees that either validate previous findings or constitute novel discoveries.
Trial Details
NCT Number NCT03058588
Lead Sponsor Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Conditions
(from sponsor)		 Leukemia
Related terms Leukemia
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov